Eyebright Medical Technology Beijing Co Ltd - Asset Resilience Ratio

Latest as of September 2025: 0.17%

Eyebright Medical Technology Beijing Co Ltd (688050) has an Asset Resilience Ratio of 0.17% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read 688050 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

CN¥6.62 Million
≈ $968.75K USD Cash + Short-term Investments

Total Assets

CN¥3.90 Billion
≈ $571.13 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2018–2024)

This chart shows how Eyebright Medical Technology Beijing Co Ltd's Asset Resilience Ratio has changed over time. See Eyebright Medical Technology Beijing Co (688050) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Eyebright Medical Technology Beijing Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Eyebright Medical Technology Beijing Co (688050) total market value.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥6.62 Million 0.17%
Total Liquid Assets CN¥6.62 Million 0.17%

Asset Resilience Insights

  • Limited Liquidity: Eyebright Medical Technology Beijing Co Ltd maintains only 0.17% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Eyebright Medical Technology Beijing Co Ltd Industry Peers by Asset Resilience Ratio

Compare Eyebright Medical Technology Beijing Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Teleflex Incorporated
NYSE:TFX
Medical Instruments & Supplies 4.50%
Touchstone International Medical Science Co Ltd
SHG:688013
Medical Instruments & Supplies 37.86%
Nyxoah
BR:NYXH
Medical Instruments & Supplies 12.40%
Crossject
PA:ALCJ
Medical Instruments & Supplies 1.31%
Ansell Ltd
AU:ANN
Medical Instruments & Supplies 4.42%
Nanosonics Ltd
AU:NAN
Medical Instruments & Supplies 51.82%
SDI Ltd
AU:SDI
Medical Instruments & Supplies 6.36%
Austco Healthcare Ltd
AU:AHC
Medical Instruments & Supplies 15.90%

Annual Asset Resilience Ratio for Eyebright Medical Technology Beijing Co Ltd (2018–2024)

The table below shows the annual Asset Resilience Ratio data for Eyebright Medical Technology Beijing Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2024-12-31 3.78% CN¥132.27 Million
≈ $19.36 Million
CN¥3.50 Billion
≈ $511.72 Million
+3.13pp
2023-12-31 0.66% CN¥20.12 Million
≈ $2.94 Million
CN¥3.06 Billion
≈ $448.04 Million
-20.82pp
2022-12-31 21.47% CN¥481.97 Million
≈ $70.53 Million
CN¥2.24 Billion
≈ $328.43 Million
+21.45pp
2021-12-31 0.02% CN¥478.90K
≈ $70.08K
CN¥2.05 Billion
≈ $299.63 Million
+0.01pp
2020-12-31 0.02% CN¥278.08K
≈ $40.69K
CN¥1.64 Billion
≈ $239.77 Million
-0.44pp
2018-12-31 0.45% CN¥2.65 Million
≈ $388.39K
CN¥586.45 Million
≈ $85.82 Million
--
pp = percentage points

About Eyebright Medical Technology Beijing Co Ltd

SHG:688050 China Medical Instruments & Supplies
Market Cap
$1.45 Billion
CN¥9.88 Billion CNY
Market Cap Rank
#7573 Global
#1851 in China
Share Price
CN¥51.11
Change (1 day)
-0.35%
52-Week Range
CN¥49.24 - CN¥82.40
All Time High
CN¥385.84
About

Eyebright Medical Technology (Beijing) Co., Ltd. engages in development, production, and commercialization of ophthalmic medical devices in China and internationally. The company offers intraocular, trimmers, capsular tension ring, defocus lense, orthokeratology, and contact lenses in the areas of surgical treatment, myopia management, and consumer vision care. It also provides solutions for opht… Read more